Decheng Capital

#Diagnostics

#Medical Device

Acquired by Ipsen

#Biopharma

Acquired by Vertex

#Biopharma

Acquired by Nuvation Bio (NYSE: NUVB)

#Biopharma

#Biopharma

Acquired by Eli Lilly

#Biopharma

#Services

#Biopharma

#Biopharma

Bristol Myers supply deal announced April 22, 2024; raised $255M Series C (Aug 23, 2023)

#Services / Manufacturing (cell therapy)

Acquired by Becton Dickinson

#Diagnostics and Tools

#Biopharma

Acquired by Regeneron

#Biopharma

#Biopharma

#Diagnostics

#Diagnostics and Tools

#Biopharma

#Biopharma

#Biopharma

#Biopharma

Acquired by Roche

#Diagnostics and Tools

Acquired by Illumina

#Diagnostics

#Biopharma

#Biopharma / Cell therapy

#Diagnostics

Launched LeviCell EOS system (Nov 21, 2023)

#Diagnostics and Tools

Regeneron/Mammoth gene editing deal announced April 25, 2024

#Diagnostics and Tools / Gene editing

Raised $60M (May 17, 2022); Nature study on prediction of pregnancy complications (Jan 5, 2022)

#Diagnostics

Closed $85M Series E (Mar 5, 2024); raised $65M equity (Jan 3, 2024)

#Medical Device

#Diagnostics and Tools / Sequencing

#Biopharma / Tools

Closed $25M financing to bring mitral valve hemi-replacement to clinic (2018)

#Medical Device

Acquired by Merck

#Biopharma

#Biopharma

Collaboration and financing activity with Roche and others (2021, 2023)

#Biopharma / Gene therapy

#Biopharma

Announced $200M Series B (June 8, 2023 / June 2, 2022 launch with financing)

#Biopharma

Acquired by Merck

#Biopharma

Raised $40M Series A (June 2, 2022); license and supply agreements with Exact Sciences (Aug 30, 2023)

#Diagnostics and Tools

Priced $250M stock offering (June 15, 2023)

#Biopharma